Mary Falcone1, Leah Bernardo2, E Paul Wileyto3, Cheyenne Allenby2, Anne Marie Burke2, Roy Hamilton4, Mario Cristancho2, Rebecca L Ashare2, James Loughead2, Caryn Lerman2. 1. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: mfalc@pennmedicine.upenn.edu. 2. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. 3. Dept of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, PA, USA. 4. Laboratory for Cognition and Neural Stimulation, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND:Transcranial direct current stimulation (tDCS) has been shown to improve measures of executive cognitive function and reduce cigarette consumption. Studies conducted to date have been small, and the results are mixed. METHODS: This randomized, double-blind, parallel arm clinical trial tested the effects of active anodal tDCS targeted to the left dorsolateral prefrontal cortex (versus sham) on 7-day smoking cessation in 106 treatment-seeking smokers. Participants received three sessions of sham (n = 35), 1 mA (n = 35), or 2 mA (n = 36) tDCS in the context of a validated smoking lapse paradigm then received brief smoking cessation counseling and completed a monitored quit attempt. The primary outcome was total number of days of abstinence confirmed via exhaled carbon monoxide. RESULTS: During the quit period, there were no effects of dose group on days of abstinence (sham, M (SD): 2.5 days (±2.5); 1 mA: 2.5 days (±2.5); 2 mA: 2.4 days (±2.3); β = -0.08; p = 0.76) or on change in daily smoking rate (sham, M (SD): 12.6 CPD (±4.8); 1 mA: -11.8 CPD (±4.4); 2 mA: -11.7 CPD (±5.3); β = 0.42, p = 0.49), nor were there effects of dose group on latency to smoke or number of cigarettes smoked during the smoking lapse paradigm. Side effects of tDCS were generally mild (<5 out of 10), and participants were not able to distinguish between active and sham treatment. CONCLUSIONS: These results do not support the efficacy of tDCS targeted to the left dorsolateral prefrontal cortex (DLPFC) for smoking cessation.
RCT Entities:
BACKGROUND: Transcranial direct current stimulation (tDCS) has been shown to improve measures of executive cognitive function and reduce cigarette consumption. Studies conducted to date have been small, and the results are mixed. METHODS: This randomized, double-blind, parallel arm clinical trial tested the effects of active anodal tDCS targeted to the left dorsolateral prefrontal cortex (versus sham) on 7-day smoking cessation in 106 treatment-seeking smokers. Participants received three sessions of sham (n = 35), 1 mA (n = 35), or 2 mA (n = 36) tDCS in the context of a validated smoking lapse paradigm then received brief smoking cessation counseling and completed a monitored quit attempt. The primary outcome was total number of days of abstinence confirmed via exhaled carbon monoxide. RESULTS: During the quit period, there were no effects of dose group on days of abstinence (sham, M (SD): 2.5 days (±2.5); 1 mA: 2.5 days (±2.5); 2 mA: 2.4 days (±2.3); β = -0.08; p = 0.76) or on change in daily smoking rate (sham, M (SD): 12.6 CPD (±4.8); 1 mA: -11.8 CPD (±4.4); 2 mA: -11.7 CPD (±5.3); β = 0.42, p = 0.49), nor were there effects of dose group on latency to smoke or number of cigarettes smoked during the smoking lapse paradigm. Side effects of tDCS were generally mild (<5 out of 10), and participants were not able to distinguish between active and sham treatment. CONCLUSIONS: These results do not support the efficacy of tDCS targeted to the left dorsolateral prefrontal cortex (DLPFC) for smoking cessation.
Authors: Xingbao Li; Lian Du; Gregory L Sahlem; Bashar W Badran; Scott Henderson; Mark S George Journal: Drug Alcohol Depend Date: 2017-02-28 Impact factor: 4.492
Authors: John R Fedota; Xiaoyu Ding; Allison L Matous; Betty Jo Salmeron; Michael R McKenna; Hong Gu; Thomas J Ross; Elliot A Stein Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-10-10
Authors: Robert C Smith; Sylvia Boules; Sanela Mattiuz; Mary Youssef; Russell H Tobe; Henry Sershen; Abel Lajtha; Karen Nolan; Revital Amiaz; John M Davis Journal: Schizophr Res Date: 2015-07-17 Impact factor: 4.939
Authors: Shirley Fecteau; Sara Agosta; Antoine Hone-Blanchet; Felipe Fregni; Paulo Boggio; Domenic Ciraulo; Alvaro Pascual-Leone Journal: Drug Alcohol Depend Date: 2014-04-16 Impact factor: 4.492
Authors: Hyein Cho; Lais B Razza; Lucas Borrione; Marom Bikson; Leigh Charvet; Tracy A Dennis-Tiwary; Andre R Brunoni; Pedro Sudbrack-Oliveira Journal: Focus (Am Psychiatr Publ) Date: 2022-01-25
Authors: Solène Pedron; Stéphanie Dumontoy; Maria Del Carmen González-Marín; Fabien Coune; Andries Van Schuerbeek; Emmanuel Haffen; Mickael Naassila; Vincent Van Waes Journal: Sci Rep Date: 2022-01-07 Impact factor: 4.379